Overcoming Barriers to Cholesterol Guideline Adherence and Icosapent Ethyl (IPE) Adoption

Overview

This engaging, interactive presentation by 2 senior faculty will keep you up to date on EPA and EPA/DHA omega-3 fatty acids in ASCVD, how icosapent ethyl, approved for ASCVD-event reduction in patients with elevated triglycerides, may be used in your practice and in ASCVD primary and secondary prevention clinics nationwide.

Click here to answer audience response questions, access downloadable slides, and ask questions to the presenter.

Learning Objectives

• Explain why escalation of therapy beyond statins with nonstatin therapies is beneficial to reduce ASCVD risk
• Discuss recent data of omega-3 fatty acids and how these data may translate into clinical practice to reduce ASCVD events
• Apply professional society recommendations and expert opinion on a case-by-case basis for patients with or at high risk of ASCVD or at risk of further CV events